MX2017010908A - Vacuna bivalente contra el virus de gripe porcina. - Google Patents

Vacuna bivalente contra el virus de gripe porcina.

Info

Publication number
MX2017010908A
MX2017010908A MX2017010908A MX2017010908A MX2017010908A MX 2017010908 A MX2017010908 A MX 2017010908A MX 2017010908 A MX2017010908 A MX 2017010908A MX 2017010908 A MX2017010908 A MX 2017010908A MX 2017010908 A MX2017010908 A MX 2017010908A
Authority
MX
Mexico
Prior art keywords
swine influenza
present
subject
bivalent
influenza virus
Prior art date
Application number
MX2017010908A
Other languages
English (en)
Inventor
Martin Vaughn Eric
Allan Eichmeyer Marc
Scott JOHNSON Wesley
L Walz Michelle
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of MX2017010908A publication Critical patent/MX2017010908A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere, entre otros, a una composición inmunogénica que comprende: a) un virus H3 vivo modificado de gripe porcina, y b) un virus H1 vivo modificado de gripe porcina. Por otra parte, la presente invención se refiere a métodos para inmunizar un sujeto que comprende la administración a tal sujeto de la composición inmunogénica de la presente invención. Más aún, la presente invención se refiere a métodos de tratamiento o prevención de los signos clínicos causados por virus de la gripe porcina en un sujeto que lo necesita, que comprende la administración al sujeto de una cantidad terapéuticamente efectiva de una composición inmunogénica de acuerdo con la presente invención.
MX2017010908A 2015-02-26 2016-02-23 Vacuna bivalente contra el virus de gripe porcina. MX2017010908A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562121181P 2015-02-26 2015-02-26
PCT/US2016/019037 WO2016137929A1 (en) 2015-02-26 2016-02-23 Bivalent swine influenza virus vaccine

Publications (1)

Publication Number Publication Date
MX2017010908A true MX2017010908A (es) 2017-12-07

Family

ID=55487152

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017010908A MX2017010908A (es) 2015-02-26 2016-02-23 Vacuna bivalente contra el virus de gripe porcina.

Country Status (13)

Country Link
US (2) US10029005B2 (es)
EP (1) EP3261664A1 (es)
JP (1) JP6722686B2 (es)
KR (1) KR20170122786A (es)
CN (1) CN107250353B (es)
AU (1) AU2016222962B2 (es)
BR (1) BR112017015789A2 (es)
CL (2) CL2017001961A1 (es)
EA (1) EA201791907A1 (es)
MX (1) MX2017010908A (es)
PH (1) PH12017501370A1 (es)
TW (1) TWI711462B (es)
WO (1) WO2016137929A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0511776B1 (pt) 2004-06-01 2016-11-29 Sinai School Medicine vírus atenuado de influenza de suínos geneticamente engenheirado, formulação imunogênica, formulação farmacêutica, uso da formulação imunogênica, uso do vírus atenuado de influenza de suínos geneticamente engenheirado, uso da formulação farmacêutica e método para produzir uma vacina, uma formulação imunogênica ou uma formulação farmacêutica
EP3261664A1 (en) 2015-02-26 2018-01-03 Boehringer Ingelheim Vetmedica GmbH Bivalent swine influenza virus vaccine
BR112020012049A2 (pt) * 2017-12-18 2020-11-24 Intervet International B.V. vacina contra vírus da influenza a suína
WO2019121414A1 (en) 2017-12-20 2019-06-27 Boehringer Ingelheim Vetmedica Gmbh Detection of modified live swine influenza virus vaccines
BR112021005255A2 (pt) * 2018-09-21 2021-06-29 Board Of Regents Of The University Of Nebraska método de produção e uso de genes para vacina contra a influenza centralizada universal
BR112021008390A2 (pt) * 2018-10-31 2021-09-28 Boehringer Ingelheim Vetmedica Gmbh Vacina de ibv h52 com proteína da espícula heteróloga
MX2021004907A (es) * 2018-10-31 2021-06-15 Boehringer Ingelheim Vetmedica Gmbh Vacuna de ibv 4/91 con proteina espicular heterologa.
MX2023012554A (es) 2018-12-12 2023-11-08 Cambridge Tech Llc Vacuna universal contra la gripe.
US11642407B2 (en) * 2020-02-28 2023-05-09 Massachusetts Institute Of Technology Identification of variable influenza residues and uses thereof
CN113186173B (zh) * 2021-04-15 2023-03-31 上海生物制品研究所有限责任公司 一种基于减毒流感病毒载体的新型冠状病毒肺炎疫苗

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4071618A (en) 1974-09-03 1978-01-31 Research Foundation For Microbial Diseases Of Osaka University Process for preparing virus disease live vaccines
JPS57136528A (en) 1981-02-09 1982-08-23 Hayashibara Biochem Lab Inc Preparation of viral vaccine
JPS5939831A (ja) 1982-08-27 1984-03-05 Biseibutsu Kagaku Kenkyusho:Kk 豚用インフルエンザウイルス不活化ワクチン
US5106619A (en) 1983-12-20 1992-04-21 Diamond Scientific Co. Preparation of inactivated viral vaccines
US4693981A (en) 1983-12-20 1987-09-15 Advanced Genetics Research Institute Preparation of inactivated viral vaccines
JPS60202827A (ja) 1984-03-28 1985-10-14 Chibaken 弱毒痘そうワクチン株
US5840520A (en) 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5786199A (en) 1989-08-28 1998-07-28 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5766601A (en) 1990-08-08 1998-06-16 University Of Massachusetts Medical Center Cross-reactive influenza a immunization
WO1993006866A2 (en) 1991-10-07 1993-04-15 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the cd2/lfa-3 interaction
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
ES2053413T3 (es) 1992-05-14 1997-11-16 Polymun Scient Immunbio Forsch Peptidos que inducen anticuerpos que neutralizan aislados de vih-1 geneticamente divergentes.
US7344722B1 (en) 1993-06-29 2008-03-18 The Regents Of The University Of Michigan Cold-adapted influenza virus
PT702085E (pt) 1994-07-18 2004-04-30 Karl Klaus Conzelmann Virus de arn de cadeia negativa nao segmentada infeccioso recombinante
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US6146873A (en) 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
DE69510207T3 (de) 1995-08-09 2007-02-15 Schweiz. Serum- & Impfinstitut Bern Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren
US5840565A (en) 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
US6264957B1 (en) 1995-09-27 2001-07-24 The United States Of America As Represented By The Department Of Health And Human Services Product of infectious respiratory syncytial virus from cloned nucleotide sequences
KR100658491B1 (ko) 1996-07-15 2006-12-18 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 에즈 레프리젠티드 바이 더 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈 클론닝된 뉴클레오타이드 서열로부터 약독화된 호흡기 세포 융합 바이러스 백신의 생산
JP2000517194A (ja) 1996-09-27 2000-12-26 アメリカン・サイアナミド・カンパニー モノネガビラレス（Ｍｏｎｏｎｅｇａｖｉｒａｌｅｓ）と称される目のウイルスにおける弱毒化の原因となる３’ゲノムプロモーター領域およびポリメラーゼ遺伝子の突然変異
KR20000075983A (ko) 1997-03-05 2000-12-26 엘. 데이예를 카렌. 헤파타이티스 ｃ 바이러스 복제를 선택적으로 저해하는 물질을 확인하기 위한 새로운 스크리닝 방법
US5891705A (en) 1997-04-08 1999-04-06 Pentose Pharmaceuticals, Inc. Method for inactivating a virus
US6884414B1 (en) 1997-04-30 2005-04-26 Mount Sinai School Of Medicine Of New York University Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents
CN1250725C (zh) 1997-05-23 2006-04-12 美国政府健康及人类服务部 从克隆的核苷酸序列制备减毒副流感病毒疫苗的方法
PT1012244E (pt) 1997-07-11 2007-08-21 Univ Yale ''rabdovírus com revestimentos remanipulados''
BR9812232A (pt) 1997-09-19 2000-07-18 American Cyanamid Co Vìrus sincicial respiratório (rsv) humano subgrupo b, isolado, recombinantemente gerado , atenuado, vacina, processo para imunizar um indivìduo para induzir proteção contra o rsv subgrupo b, composição, processo para produzir rsv subgrupo b infeccioso atenuado, e, molécula isolada de ácido nucleico
ATE384126T1 (de) 1998-06-12 2008-02-15 Sinai School Medicine Interferon induzierende genetisch veränderte attenuierte viren
DK1086207T3 (da) 1998-06-12 2007-05-29 Sinai School Medicine Hidtil ukendte fremgangsmåder og inteferon-deficiente substrater til opformering af vira
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
DE122007000061I2 (de) 1999-07-14 2011-07-21 Sinai School Medicine In vitro-rekonstitution von segmentierten negativstrang-rna-viren.
ATE299943T1 (de) 2000-03-02 2005-08-15 Polymun Scient Immunbio Forsch Rekombinantes influenza a virus
WO2001077394A1 (en) 2000-04-10 2001-10-18 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
DE10020505A1 (de) 2000-04-26 2001-10-31 Conzelmann Karl Klaus RSV NS Proteine antagonisieren die Interferon (IFN) Antwort
DK1358319T3 (da) 2000-09-25 2009-10-05 Polymun Scient Immunbio Forsch Levende influenzavaccine og fremgangsmåde til fremstilling heraf
CA2505949A1 (en) 2002-11-13 2004-05-27 Rutgers, The State University Process for designing inhibitors of influenza virus non-structural protein 1
BRPI0511776B1 (pt) 2004-06-01 2016-11-29 Sinai School Medicine vírus atenuado de influenza de suínos geneticamente engenheirado, formulação imunogênica, formulação farmacêutica, uso da formulação imunogênica, uso do vírus atenuado de influenza de suínos geneticamente engenheirado, uso da formulação farmacêutica e método para produzir uma vacina, uma formulação imunogênica ou uma formulação farmacêutica
US8137676B2 (en) 2005-02-15 2012-03-20 Mount Sinai School Of Medicine Genetically engineered equine influenza virus and uses thereof
US20070116717A1 (en) 2005-08-01 2007-05-24 Shneider Alexander M Influenza vaccine compositions and methods
AT502275B8 (de) 2005-08-08 2007-08-15 Greenhills Biotechnology Res D Immunantwort-induzierende zusammensetzungen
US9387242B2 (en) 2005-12-02 2016-07-12 Icahn School Of Medicine At Mount Sinai Chimeric viruses presenting non-native surface proteins and uses thereof
US7507411B2 (en) 2006-06-23 2009-03-24 University Of Saskatchewan Attenuated influenza NS1 variants
US9217157B2 (en) 2009-07-27 2015-12-22 Icahn School Of Medicine At Mount Sinai Recombinant influenza viruses and uses thereof
CN102166352B (zh) * 2011-04-13 2013-01-23 华威特（北京）生物科技有限公司 猪流感二价灭活疫苗的制备方法及其产品
US20130189303A1 (en) 2011-08-02 2013-07-25 Yan Zhou Recombinant swine influenza virus and uses thereof
US9017694B2 (en) * 2011-10-07 2015-04-28 Medimmune, Llc Swine influenza hemagglutinin variants
CN103468647B (zh) * 2013-09-03 2015-04-22 华中农业大学 猪流感h1n1和h3n2亚型的二价灭活疫苗
EP3261664A1 (en) 2015-02-26 2018-01-03 Boehringer Ingelheim Vetmedica GmbH Bivalent swine influenza virus vaccine

Also Published As

Publication number Publication date
EA201791907A1 (ru) 2018-02-28
CN107250353B (zh) 2021-07-23
CL2017001961A1 (es) 2018-04-20
TW201701900A (zh) 2017-01-16
JP6722686B2 (ja) 2020-07-15
TWI711462B (zh) 2020-12-01
US10029005B2 (en) 2018-07-24
BR112017015789A2 (pt) 2018-03-27
CN107250353A (zh) 2017-10-13
AU2016222962A1 (en) 2017-07-13
KR20170122786A (ko) 2017-11-06
US20160250318A1 (en) 2016-09-01
JP2018512388A (ja) 2018-05-17
PH12017501370A1 (en) 2017-12-18
CL2018002692A1 (es) 2019-01-18
AU2016222962B2 (en) 2020-05-21
WO2016137929A1 (en) 2016-09-01
EP3261664A1 (en) 2018-01-03
US10905756B2 (en) 2021-02-02
US20180289795A1 (en) 2018-10-11

Similar Documents

Publication Publication Date Title
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
MX2022006603A (es) Vacuna contra el virus de la influenza de amplio espectro.
PH12018500856A1 (en) Respiratory syncytial virus vaccine
EP4233898A3 (en) Influenza mrna vaccines
EP4349404A3 (en) Respiratory virus vaccines
MX369469B (es) Vacuna contra el virus respiratorio sincitial.
MX2017001406A (es) Agentes a base de flagelina y usos de los mismos, incluyendo vacunación efectiva.
MX2017012220A (es) Composiciones adyuvantes y metodos relacionados.
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
MX2018015506A (es) Vacuna contra virus de bronquitis infecciosa.
BR112017003462A2 (pt) coronavírus bovino atenuado, vacina, e, método de vacinação de um bovino.
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
EA201991041A1 (ru) Вакцина против свиного парвовируса и вируса свиного репродуктивного и респираторного синдрома и способы ее получения
MX2022000746A (es) Dimetilfumarato y regimenes de vacunacion.
BR112016028316A2 (pt) composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
BR112018074910A2 (pt) composição imunológica, e, método de indução de uma resposta imunológica contra o vírus da influenza equina em um sujeito
EA201892003A1 (ru) Лечение атопического дерматита собак
EA201792593A1 (ru) Пестивирусные вакцины против врожденного тремора
MX2017015004A (es) Estrategia de vacuna basada en nanoparticulas contra el virus de la influenza porcina.
BR112016030728A2 (pt) método para tratar ou prevenir uma inflamação induzida por bactérias em um indivíduo, composição imunogênica, composição farmacêutica, uso da composição imunogênica, método para produzir uma composição imunogênica, e, método para tratar ou prevenir uma doença
MX2017006744A (es) Composiciones adyuvantes y metodos relacionados.
EA202191147A1 (ru) Вакцина виб h52 с гетерологичным шиповидным белком
EA202191145A1 (ru) Вакцина виб 4/91 с гетерологичным шиповидным белком